Bartter syndrome medical therapy: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
(8 intermediate revisions by the same user not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
Main article: [[Bartter syndrome|Bartter syndrome]]
{{Bartter syndrome}}
{{Bartter syndrome}}
{{CMG}}{{AE}}{{TAM}}
{{CMG}}{{AE}}{{TAM}}
==Overview==
==Overview==
[[Prostaglandin]] synthetase inhibitors suppress the production of [[prostaglandin]]. [[Potassium chloride]] supplements are given for [[hypokalemia]]. [[Spironolactone]], Amiloride, [[Triamterene]], [[ ACEI|Angiotensin-converting enzyme (ACE) inhibitors]], [[NSAIDS|Nonsteroidal drug anti-inflammatory drugs]] (NSAID) are given to patients for the treatment of [[Bartter syndrome]]. [[Growth hormone]] (GH) is given for growth retardation. [[Calcium]] or [[magnesium]] supplements are given for [[muscle spasm]] and [[tetany]].
==Medical Therapy==
==Medical Therapy==
*Prostaglandin synthetase inhibitors suppress the production of prostaglandin. This corrects all the chemical features of the syndrome except the urinary loss of potassium.<ref name="pmid820194">{{cite journal| author=Gill JR, Frölich JC, Bowden RE, Taylor AA, Keiser HR, Seyberth HW | display-authors=etal| title=Bartter's syndrome: a disorder characterized by high urinary prostaglandins and a dependence of hyperreninemia on prostaglandin synthesis. | journal=Am J Med | year= 1976 | volume= 61 | issue= 1 | pages= 43-51 | pmid=820194 | doi=10.1016/0002-9343(76)90029-2 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=820194  }} </ref>
*Prostaglandin synthetase inhibitors suppress the production of [[prostaglandin]]. This corrects all the chemical features of the syndrome except the urinary loss of [[potassium]].<ref name="pmid820194">{{cite journal| author=Gill JR, Frölich JC, Bowden RE, Taylor AA, Keiser HR, Seyberth HW | display-authors=etal| title=Bartter's syndrome: a disorder characterized by high urinary prostaglandins and dependence of hyperreninemia on prostaglandin synthesis. | journal=Am J Med | year= 1976 | volume= 61 | issue= 1 | pages= 43-51 | pmid=820194 | doi=10.1016/0002-9343(76)90029-2 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=820194  }} </ref>
While patients should be encouraged to include liberal amounts of sodium and potassium in their diet, potassium supplements are usually required, and [[spironolactone]] is also used to reduce potassium loss. [[Nonsteroidal antiinflammatory drugs]] (NSAIDs) can be used as well, and are particularly helpful in patients with neonatal Bartter's syndrome. [[ACE inhibitor|Angiotensin-converting enzyme (ACE) inhibitors]] can also be used.
*[[Hypokalemia]] should be treated. [[Potassium chloride]] supplements are preferred salt because of the coexisting [[chloride]] deficiencies in these patients.
*[[Spironolactone]], aldosterone antagonist.
*Amiloride reduces potassium and hydrogen excretion, by inhibiting epithelial sodium channels (ENaC).
*[[Triamterene]] decreases [[calcium]] excretion and increases [[magnesium]] loss.
*[[Angiotensin-converting enzyme (ACE) inhibitors]], such as [[captopril]], [[enalapril]] and [[lisinopril]].
*Nonsteroidal drug anti-inflammatory drugs (NSAID) such as [[indomethacin]] and [[naproxen]] which decrease the activity of the enzyme [[cyclo-oxygenase]] (COX) which increases [[prostaglandin]] synthesis.
*[[Growth hormone]] (GH) for [[growth retardation]].
*[[Calcium]] or [[magnesium]] supplements in the presence of [[muscle spasm]] and [[tetany]].<ref name="pmid26140272">{{cite journal| author=Al Shibli A, Narchi H| title=Bartter and Gitelman syndromes: Spectrum of clinical manifestations caused by different mutations. | journal=World J Methodol | year= 2015 | volume= 5 | issue= 2 | pages= 55-61 | pmid=26140272 | doi=10.5662/wjm.v5.i2.55 | pmc=4482822 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26140272  }} </ref>
 
==References==
==References==
{{Reflist|2}}
{{Reflist|2}}

Latest revision as of 20:57, 5 August 2020

Main article: Bartter syndrome

Bartter syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Bartter syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Bartter syndrome medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Bartter syndrome medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Bartter syndrome medical therapy

CDC on Bartter syndrome medical therapy

Bartter syndrome medical therapy in the news

Blogs on Bartter syndrome medical therapy

Directions to Hospitals Treating Bartter syndrome

Risk calculators and risk factors for Bartter syndrome medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Tayyaba Ali, M.D.[2]

Overview

Prostaglandin synthetase inhibitors suppress the production of prostaglandin. Potassium chloride supplements are given for hypokalemia. Spironolactone, Amiloride, Triamterene, Angiotensin-converting enzyme (ACE) inhibitors, Nonsteroidal drug anti-inflammatory drugs (NSAID) are given to patients for the treatment of Bartter syndrome. Growth hormone (GH) is given for growth retardation. Calcium or magnesium supplements are given for muscle spasm and tetany.

Medical Therapy

References

  1. Gill JR, Frölich JC, Bowden RE, Taylor AA, Keiser HR, Seyberth HW; et al. (1976). "Bartter's syndrome: a disorder characterized by high urinary prostaglandins and dependence of hyperreninemia on prostaglandin synthesis". Am J Med. 61 (1): 43–51. doi:10.1016/0002-9343(76)90029-2. PMID 820194.
  2. Al Shibli A, Narchi H (2015). "Bartter and Gitelman syndromes: Spectrum of clinical manifestations caused by different mutations". World J Methodol. 5 (2): 55–61. doi:10.5662/wjm.v5.i2.55. PMC 4482822. PMID 26140272.


Template:WikiDoc Sources